Rep. Josh Gottheimer Buys Genmab A/S (NASDAQ:GMAB) Shares

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genmab A/S stock on January 16th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $19.69 on Thursday. The company has a 50 day simple moving average of $20.68 and a two-hundred day simple moving average of $23.21. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The company has a market capitalization of $13.03 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 0.54 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, analysts forecast that Genmab A/S will post 1.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently added to or reduced their stakes in the stock. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S in the 4th quarter worth $33,804,000. Two Sigma Advisers LP lifted its holdings in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after acquiring an additional 280,900 shares during the period. Russell Investments Group Ltd. boosted its position in Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock worth $10,660,000 after purchasing an additional 508,104 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Genmab A/S by 3,049.3% in the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock worth $8,507,000 after purchasing an additional 394,670 shares during the last quarter. Finally, Trexquant Investment LP grew its stake in shares of Genmab A/S by 495.1% during the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock valued at $7,929,000 after purchasing an additional 316,089 shares during the period. Institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

GMAB has been the topic of a number of analyst reports. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $42.17.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.